Association of metabolic syndrome in polycystic ovarian syndrome: an observational study
Tóm tắt
To find out the prevalence of metabolic syndrome (MBS) in women with PCOS and assess their strength of association. Methods: Total 50 apparently healthy non-pregnant PCOS subjects of 15 to 35 years were studied for having the features of MBS from May 2006 to April 2007. MBS was diagnosed by National Cholesterol Education Program’s Adult Treatment Panel III 2001 criteria. Student’s t test & Mann-Whitney U test were used for statistical analysis. 21 subjects out of 50 (42%) met criteria for the MBS. 15(71.5%) belonged to 26–35 years and six (20.7%) in 15–25 years. Prevalence of waist circumference > 88 cm were noted in 34%, HDL cholesterol< 50 mg/dl in 50%, triglycerides ≥ 150 mg/dl in 40%, BP ≥130/85 mm Hg in 50% and FBS≥ 110 mg/dl in 16%. Women with higher insulin resistance and free testosterone levels significantly (P<0.01) correlated with higher prevalence of MBS. The metabolic syndrome and its individual components are common in PCOS, particularly among women with hyperinsulinemia and hyperandrogenism.
Tài liệu tham khảo
Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89(6):2745–2749.
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
Legro RS, Kunselman AR, Dodson WC, et al Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.
Talbott EO, Guzick DS, Sutton-Tyrrell K, et al Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414–2421.
Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581–586.
Haeffner SM, Valdez RA, Hazuda HP, et al Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715–722
Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607
Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–3421
Alberti KG, Zimmet P, Shaw J, Group IDFETFC: The metabolic syndrome-a new world wide definition. Lancet 2005;366:1059–1062.
Ehrmann DA, Liljenquist DR, Kasza K, et al PCOS/Troglitazone Study Group. Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2006;91(1):48–53.
Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005;106:131–137.
Rabelo AM, Vick MR. Association between the PCOS and the metabolic syndrome in Puerto rico. P R Health Sci J 2005;24(3):203–206.
Apridonidze T, Essah PA, Iuorno MJ, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.
Misra A, Wasir JS, Pandey RM. An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians. Diab Care 2005;28:398–403.